Back to MRK
Phase 3
Development Phase
0
Upcoming Catalysts
2
Historical Events
1
Regulatory Approvals
Competitive Landscape
0 competitors in Respiratory Syncytial Viruses
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/15/2026
Enflonsia
Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
